ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle

A new group of bispecifics targeting CD20 is on the rise in lymphoma, and first-in-class Roche is digging its trench deeper with new updates for Lunsumio and market-nearing glofitamab as potential competition from AbbVie and Regeneron draw near.